CERO THERAPEUTICS HOLDINGS, INC. Research and Development Expense
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Research and Development Expense of $1.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- CERO THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $1.74M, a 36.96% decline year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $2.34M, a 19.58% decline year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $2.39M, a 34.50% increase year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2025-06-30 was $2.75M, a 1.46% increase year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. research and development expense for fiscal 2023 was $5.29M.
| Period end | Research and Development Expense 1 month | Research and Development Expense 2 month | Research and Development Expense 3 month | Research and Development Expense 5 month | Research and Development Expense 6 month | Research and Development Expense 8 month | Research and Development Expense 9 month | Research and Development Expense 11 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.74M 10-Q · filed 2026-08-14 | $4.07M 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | $2.34M 10-Q · filed 2026-05-15 | ||||||||
| 2025-09-30 | $2.39M 10-Q · filed 2025-11-19 | $5.14M derived: sum of 2 quarters · filed 2026-08-14 | $8.05M 10-Q · filed 2025-11-19 | ||||||
| 2025-06-30 | $2.75M 10-Q · filed 2026-08-14 | $5.66M 10-Q · filed 2026-08-14 | |||||||
| 2025-03-31 | $2.91M 10-Q · filed 2026-05-15 | ||||||||
| 2024-12-31 | $6.32M 10-K · filed 2025-04-15 | ||||||||
| 2024-09-30 | $1.77M 10-Q · filed 2025-11-19 | $4.49M derived: sum of 2 quarters · filed 2025-11-19 | $5.39M 10-Q · filed 2025-11-19 | ||||||
| 2024-06-30 | $2.71M 10-Q · filed 2025-08-22 | $3.62M 10-Q · filed 2025-08-22 | |||||||
| 2024-03-31 | $904.01K 10-Q · filed 2025-05-15 | ||||||||
| 2024-02-13 | $764.19K 10-Q · filed 2025-11-19 | ||||||||
| 2023-12-31 | $1.02M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-04-15 | $2.30M derived: sum of 2 quarters · filed 2025-04-15 | $3.49M derived: sum of 3 quarters · filed 2025-04-15 | $5.29M 10-K · filed 2025-04-15 | |||||
| 2023-09-30 | $1.28M 10-Q/A · filed 2024-11-20 | $2.47M derived: sum of 2 quarters · filed 2024-11-20 | $4.27M 10-Q/A · filed 2024-11-20 | ||||||
| 2023-06-30 | $1.19M 10-Q · filed 2024-08-14 | $2.99M 10-Q · filed 2024-08-14 | |||||||
| 2023-03-31 | $1.80M 10-Q · filed 2024-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |